425: Waters Corporation and BD Announce Strategic Combination with Augusta SpinCo to Double Addressable Market and Enhance Financial Outlook

Waters Corporation and Becton, Dickinson and Company announced a proposed business combination between Waters and BD's Augusta SpinCo Corporation, aiming to double Waters' addressable market to $40 billion and enhance financial outlook.

Summary

• A proposed business combination has been announced between Waters Corporation and Augusta SpinCo Corporation, a wholly owned subsidiary of Becton, Dickinson and Company (BD).
• The combination is expected to significantly increase Waters' recurring revenue and double its addressable market to $40 billion.
• The transaction will accelerate Waters' strategic expansion into multiple fast-growing adjacencies, including bioseparations, bioanalytical characterization, and multiplex diagnostics.
• The combined entity is projected to achieve an industry-leading financial outlook, characterized by enhanced growth and improved margins.
• The transaction is expected to be accretive to adjusted Earnings Per Share (EPS) in the first year following closing.
• For BD, this combination represents a strategic step towards becoming a pure-play medical technology company, focusing on key healthcare growth trends such as biologic drug delivery, connected care, healthcare automation, and solutions for chronic diseases.

Sentiment

Score: 8

Explanation: The document is highly positive, outlining significant strategic and financial benefits for both Waters and BD, including market expansion, revenue growth, margin improvement, and EPS accretion. The tone is optimistic about the future of the combined entity and BD's strategic repositioning. Risks are disclosed in a standard cautionary statement, but the overall message is one of strong strategic fit and value creation.

Positives

• The combination is expected to double Waters' addressable market to $40 billion.
• It is anticipated to increase Waters' recurring revenue.
• The transaction accelerates Waters' strategy by expanding into high-value, long-term growth adjacencies: bioseparations, bioanalytical characterization, and multiplex diagnostics.
• The combined entity is projected to have an industry-leading financial outlook with enhanced growth and improved margins.
• The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
• The combined portfolios will offer unparalleled value with best-in-class products positioned in large and attractive regulated, high-volume end-markets.
• The transaction allows BD to become a pure-play medical technology company, focusing on major healthcare growth trends.

Risks

• One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
• The combined company may face difficulties in implementing its business strategy.
• Difficulties and delays may occur in the combined company achieving revenue and cost synergies.
• The combined company may be unable to retain and hire key personnel.
• The occurrence of any event could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the proposed transaction may affect its timing or occurrence or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined operations.
• Changes in general economic and/or industry-specific conditions or any volatility resulting from tariffs could affect outcomes.
• Actions by third parties, including government agencies, could impact the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• There is a risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• The pendency of the proposed transaction may disrupt management time from ongoing business operations.
• Other effects of the pendency of the proposed transaction on the relationship of any of the parties with their employees, customers, suppliers, or other counterparties could occur.

Future Outlook

The proposed combination is expected to create an industry-leading financial outlook for the combined entity, characterized by enhanced growth and improved margins. It is also anticipated to be accretive to adjusted EPS in the first year post-closing. The transaction aims to double Waters' addressable market to $40 billion and accelerate its expansion into high-growth adjacencies. For BD, the outlook is to become a pure-play medical technology company focused on key healthcare growth trends.

Management Comments

• "There are three key reasons why this combination is such a strong strategic fit. First, the diversification in the portfolio increases our recurring revenue and doubles our addressable market to $40 billion, while keeping us in regulated, high-volume end-markets where demand is driven by consistent needs like pill count, patient testing, and launches of novel therapeutics." Udit Batra, CEO and President of Waters Corporation.
• "Second, it builds on Waters successful transformation over the last 5 years and accelerates our strategy of expanding into multiple fast-growing adjacencies all at once, including bioseparations, bioanalytical characterization, and multiplex diagnostics. These are areas that we have long identified as offering high-value, long-term growth." Udit Batra, CEO and President of Waters Corporation.
• "Lastly, this transaction creates an industry-leading financial outlook with enhanced growth, improved margins, and is expected to be accretive to adjusted EPS in the first year post-closing." Udit Batra, CEO and President of Waters Corporation.
• "I agree, each of those three benefits is extremely compelling, as together with Waters, the combined businesses will build on each others strengths to create a leading life science company that serves important high growth industries with significant unmet needs – advancing human health and well-being in ways they couldn’t have achieved individually." Tom Polen, Chairman, CEO and President of Becton, Dickinson and Company.
• "This transaction also represents a significant step forward in making BD a pure-play medical technology company at the forefront of healthcares biggest growth trends from biologic drug delivery to connected care and healthcare automation, to solutions for treating chronic disease such as cancer, vascular disease and incontinence." Tom Polen, Chairman, CEO and President of Becton, Dickinson and Company.

Industry Context

This proposed combination reflects a trend towards consolidation and specialization within the life sciences and medical technology sectors. Waters aims to expand its market reach and diversify into high-growth analytical and diagnostic adjacencies, while BD seeks to streamline its portfolio to become a more focused pure-play medical technology company. This strategic move allows both entities to better compete in their respective core and expanding markets, addressing significant unmet needs in healthcare.

Legal Proceedings

• Potential stockholder litigation in connection with the proposed transaction.
• Other litigation, settlements, or investigations that may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Expected value unlock for Waters and BD shareholders due to anticipated enhanced growth, improved margins, and EPS accretion. Potential for litigation related to the transaction.
• Customers: The combined portfolios are expected to offer unparalleled value with best-in-class products.
• Partners: Expected value unlock for partners.
• Employees (Associates): Potential for disruption of management time from ongoing business operations due to the pendency of the transaction, and other effects on relationships; risk of inability to retain and hire key personnel.

Next Steps

• Waters Corporation intends to file a registration statement on Form S-4, which will include a preliminary and definitive proxy statement/prospectus.
• Augusta SpinCo Corporation intends to file a registration statement on Form 10, which will serve as an information statement/prospectus.
• Investors and security holders of Waters and BD are urged to read the proxy statement/prospectus, the information statement/prospectus, and any other documents filed with the SEC, as well as any amendments or supplements, when they become available.
• Completion of the proposed transaction is subject to various closing conditions, including certain regulatory approvals and the required approval by Waters' stockholders.

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Augusta SpinCo Corporation, Merger, Acquisition, Business Combination, Life Sciences, Medical Technology, Bioseparations, Bioanalytical Characterization, Multiplex Diagnostics, SEC Filing, Form 425, EPS Accretion, Market Expansion, Strategic Growth, Pure-Play